Please login to the form below

Valid News, Market Access Insights, Issue 3

Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market.

Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market. So for Issue 3 of Valid News, we’re discussing developments from across the globe. It’s also important to be able to access the insights, support and advice you need, anytime, anywhere, which is why we’ve launched virtual workshops – making our expertise always accessible. You can find all the information you need on these, and more, inside.

Download the newsletter now for insight into:

  • our predictions for the future of market access
  • the impact of free prescriptions
  • why medicinal products are denied in France
  • how to prepare for reimbursement
  • the vicious cycle of contracting and tendering
  • explaining the price of your product
  • virtual workshops to elevate value, pricing and market access strategies

Download the newsletter now here: https://www.validinsight.com/resource-center/valid-news-market-access-insights-issue-3/

25th October 2019

Share

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer's perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of RWE in Is real-world evidence the holy grail: Finding the balance.
Valid Insight
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE.
Valid Insight
RWE Blog 2: Payers use real-world data cautiously
Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.
Valid Insight
RWE Blog 1: Real-world challenges and real-world data
This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access.
Valid Insight
Valid News, Market Access Insights, Issue 3
Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market.
Valid Insight